Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (14206)	7/23/2000 4:42:42 PM
From: Robert K.	Respond to of 17367

Speaking of DNA>"The activation and adherence of leukocytes to the venular endothelium are critical steps in the pathogenesis of generalized microvascular injury following hemorrhagic shock. Previous studies have shown that the integrins CD11/CD18 play a significant role in this interaction. The purpose of this study is to examine the efficacy of anti-LFA-1ß, an antibody to CD11a/CD18, in attenuating leukocyte adherence before, during, and after hemorrhagic shock. Following a control period, blood was withdrawn to reduce the mean arterial pressure to 40 mm Hg for 30 min in urethane-anesthetized rats. Mesenteric venules in a transilluminated segment of the small intestines were examined to quantitate leukocyte adherence using intravital microscopy. In sham-operated rats (control), there was minimal to no leukocyte adherence throughout the experiment. Hemorrhagic shock resulted in significant leukocyte adherence during resuscitation (10.8 ± 1.7 cells/100 µm, P < 0.01) when compared to control. Anti-LFA-1ß, when given before hemorrhagic shock, significantly attenuated leukocyte adherence during resuscitation (1.1 ± 0.8, P < 0.01) when compared with hemorrhagic shock alone. This protective effect of anti-LFA-1ß on leukocyte adherence was even demonstrated when it was given during (1.6 ± 0.3, P < 0.01) and 10 min after hemorrhagic shock (5.8 ± 0.4, P < 0.05). These results suggest that anti-LFA-1ß may be of potential therapeutic benefit against microvascular injury caused by hemorrhagic shock." Cacaito & stockdoc what do you make of this? Just curious.